Royal Bank of Canada’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3K | Buy |
742
+528
| +247% | +$2.68K | ﹤0.01% | 6569 |
|
|
2025
Q4 | $1K | Sell |
214
-152,090
| -100% | -$578K | ﹤0.01% | 6976 |
|
|
2025
Q3 | $486K | Sell |
152,304
-91,243
| -37% | -$205K | ﹤0.01% | 4497 |
|
|
2025
Q2 | $552K | Buy |
+243,547
| New | +$393K | ﹤0.01% | 4385 |
|
|
2024
Q3 | – | Sell |
-248
| Closed | – | – | 6945 |
|
|
2024
Q2 | $0 | Buy |
+248
| New | +$494 | ﹤0.01% | 7123 |
|
|
2024
Q1 | – | Sell |
-798
| Closed | -$1K | – | 7090 |
|
|
2023
Q4 | $1K | Buy |
+798
| New | +$1.05K | ﹤0.01% | 6907 |
|
|
2023
Q3 | – | Sell |
-484
| Closed | -$1K | – | 7152 |
|
|
2023
Q2 | $1K | Buy |
484
+384
| +384% | +$638 | ﹤0.01% | 6982 |
|
|
2023
Q1 | $0 | Hold |
100
| – | – | ﹤0.01% | 7131 |
|
|
2022
Q4 | $0 | Sell |
100
-177
| -64% | -$262 | ﹤0.01% | 7294 |
|
|
2022
Q3 | $0 | Buy |
277
+177
| +177% | +$272 | ﹤0.01% | 7497 |
|
|
2022
Q2 | $0 | Sell |
100
-3,985
| -98% | -$7.63K | ﹤0.01% | 7414 |
|
|
2022
Q1 | $11K | Sell |
4,085
-10,927
| -73% | -$42K | ﹤0.01% | 6900 |
|
|
2021
Q4 | $64K | Buy |
15,012
+8,350
| +125% | +$48.9K | ﹤0.01% | 6224 |
|
|
2021
Q3 | $35K | Buy |
6,662
+1,122
| +20% | +$6.01K | ﹤0.01% | 6360 |
|
|
2021
Q2 | $35K | Buy |
5,540
+1,532
| +38% | +$11.9K | ﹤0.01% | 6258 |
|
|
2021
Q1 | $31K | Buy |
4,008
+3,908
| +3,908% | +$30.9K | ﹤0.01% | 6179 |
|
|
2020
Q4 | $1K | Sell |
100
-65
| -39% | -$464 | ﹤0.01% | 6932 |
|
|
2020
Q3 | $1K | Sell |
165
-112
| -40% | -$831 | ﹤0.01% | 6407 |
|
|
2020
Q2 | $3K | Sell |
277
-51
| -16% | -$474 | ﹤0.01% | 6170 |
|
|
2020
Q1 | $3K | Sell |
328
-614
| -65% | -$4.28K | ﹤0.01% | 6175 |
|
|
2019
Q4 | $8K | Buy |
942
+842
| +842% | +$5.68K | ﹤0.01% | 6211 |
|
|
2019
Q3 | $1K | Hold |
100
| – | – | ﹤0.01% | 6423 |
|
|
2019
Q2 | $1K | Hold |
100
| – | – | ﹤0.01% | 6684 |
|
|
2019
Q1 | $1K | Hold |
100
| – | – | ﹤0.01% | 6628 |
|
|
2018
Q4 | $2K | Sell |
100
-1,141
| -92% | -$16.9K | ﹤0.01% | 6435 |
|
|
2018
Q3 | $23K | Buy |
1,241
+957
| +337% | +$21.8K | ﹤0.01% | 5599 |
|
|
2018
Q2 | $6K | Buy |
+284
| New | +$7.25K | ﹤0.01% | 5975 |
|
|
2018
Q1 | – | Sell |
-307
| Closed | -$6K | – | 6409 |
|
|
2017
Q4 | $6K | Sell |
307
-2,165
| -88% | -$44.9K | ﹤0.01% | 6028 |
|
|
2017
Q3 | $45K | Buy |
2,472
+2,427
| +5,393% | +$37.9K | ﹤0.01% | 5476 |
|
|
2017
Q2 | $1K | Sell |
45
-682
| -94% | -$10.3K | ﹤0.01% | 6375 |
|
|
2017
Q1 | $13K | Sell |
727
-136
| -16% | -$1.79K | ﹤0.01% | 5834 |
|
|
2016
Q4 | $9K | Buy |
+863
| New | +$10.5K | ﹤0.01% | 6116 |
|
Other funds holding CTMX
KCM
PA
VA
VCM
Royal Bank of Canada's CTMX Position: Q1 2026 in Review
Royal Bank of Canada increased its CytomX Therapeutics (CTMX) stake by 247% in Q1 2026, buying an estimated $2.68K and bringing the position to 742 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #6569.
Royal Bank of Canada first reported a position in CTMX in Q4 2016 and has held it in 32 quarters since. The position peaked at $552K in Q2 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.
- Royal Bank of Canada held 742 shares of CytomX Therapeutics worth $3K as of Q1 2026.
- Royal Bank of Canada bought 528 CytomX Therapeutics shares in Q1 2026, an estimated $2.68K.
- CytomX Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6569 holding.
- Royal Bank of Canada first reported a position in CytomX Therapeutics in Q4 2016 and has held it in 32 quarters since.
- Royal Bank of Canada's CytomX Therapeutics position peaked at $552K in Q2 2025.
- 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.